Myriad Genetics (MYGN) Projected to Post Earnings on Monday

Myriad Genetics (NASDAQ:MYGN) is projected to release its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect Myriad Genetics to post earnings of ($0.02) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Myriad Genetics Price Performance

Myriad Genetics stock opened at $4.49 on Monday. The business’s 50-day simple moving average is $6.11 and its 200 day simple moving average is $6.65. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32. The stock has a market cap of $418.51 million, a price-to-earnings ratio of -1.04 and a beta of 1.90. Myriad Genetics has a 12-month low of $3.76 and a 12-month high of $15.47.

Institutional Trading of Myriad Genetics

Large investors have recently bought and sold shares of the business. Alliancebernstein L.P. raised its holdings in Myriad Genetics by 1.8% during the 3rd quarter. Alliancebernstein L.P. now owns 101,234 shares of the company’s stock worth $732,000 after buying an additional 1,784 shares during the period. Legal & General Group Plc increased its position in shares of Myriad Genetics by 1.0% during the second quarter. Legal & General Group Plc now owns 237,688 shares of the company’s stock worth $1,262,000 after acquiring an additional 2,313 shares in the last quarter. Quarry LP lifted its position in Myriad Genetics by 155.6% in the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after acquiring an additional 2,657 shares in the last quarter. Franklin Resources Inc. boosted its stake in Myriad Genetics by 2.7% in the 4th quarter. Franklin Resources Inc. now owns 103,374 shares of the company’s stock worth $636,000 after purchasing an additional 2,714 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in Myriad Genetics by 2,333.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after purchasing an additional 4,480 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MYGN has been the topic of several recent research reports. Zacks Research lowered shares of Myriad Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. TD Cowen reaffirmed a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Wells Fargo & Company upped their target price on shares of Myriad Genetics from $6.00 to $6.50 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Piper Sandler cut their price target on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.44.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.